BOSTON, Massachusetts — October 16, 2025 — Leads & Copy —BPGbio Inc. will present two posters on its lead investigational drug BPM31510 for Glioblastoma (GBM) at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany, from October 17 – 20. BPGbio has completed the phase 2b enrollment of GBM trial late August this year.
The presentations will highlight insights into the mitochondrial-targeting therapy BPM31510, including biomarker-driven pharmacodynamic analyses in patients with recurrent GBM and interim progress from an ongoing Phase 2 trial in newly diagnosed GBM patients.
Niven R. Narain, Ph.D., President and CEO of BPGbio, expressed excitement about sharing the data at ESMO, highlighting BPM31510’s mechanism of reprogramming tumor metabolism. He also acknowledged the collaboration and support from partners like Stanford and Aixial Group.
One poster presentation will cover an interim analysis of a Phase 2 study of BPM31510 with Vitamin K in combination with standard chemoradiation in newly diagnosed GBM patients. The other will feature biomarker analysis of BPM31510 in recurrent, Bevacizumab-Refractory High-Grade Glioma, showcasing effects on metabolic and tumor progression markers.
BPM31510IV is BPGbio’s lead candidate in late-stage development for aggressive solid tumors, including GBM and pancreatic cancer. It has received Orphan Drug Designation by the FDA for GBM, pancreatic cancer, and epidermolysis bullosa (EB), as well as Rare Pediatric Disease Designation for primary CoQ10 deficiency and EB.
Media contact: Media@bpgbio.com
Source: BPGbio
